Core Viewpoint - cbdMD, Inc. (YCBD) is demonstrating steady growth and improving financial health through strategic initiatives and disciplined cost management [1][2][5] Financial Performance - YCBD reported revenue of approximately $4.72 million for the period, slightly above the estimated $4.70 million, indicating steady growth [2][5] - The company has significantly reduced its operating loss to $2.1 million, an improvement from the $3.3 million loss in fiscal 2024, attributed to disciplined cost management and investments in quality and science [2][5] Financial Position - YCBD has strengthened its financial position through a $2.25 million Series C Preferred Stock private placement, with approximately $2.1 million available for working capital and strategic initiatives after expenses [3] - The Series C shares offer a 10% annual dividend and conversion options, providing flexibility for investors [3] - The company maintains a low debt-to-equity ratio of 0.16, indicating modest debt levels, and a current ratio of 1.56, suggesting good liquidity to cover short-term liabilities [4]

Core Viewpoint - cbdMD, Inc. has entered into securities purchase agreements with institutional investors, issuing 1,000,000 shares of Series C Convertible Preferred Stock for gross proceeds of $2.25 million, aimed at supporting working capital and strategic initiatives [1][2]. Financial Details - The net proceeds from the issuance are approximately $2.1 million, which will be used for general corporate purposes and ongoing strategic initiatives [1]. - The Series C shares carry a 10% annual dividend and can be converted into common stock at an initial price of $2.25 per share, with anti-dilution protections [1]. Company Overview - cbdMD, Inc. is a leading wellness company that offers a range of U.S.-produced, hemp-derived cannabinoid products, including CBD, CBG, and CBN [4]. - The company emphasizes quality, innovation, and transparency, distributing products online and through retail partners across the United States [4].

Core Points - cbdMD, Inc. has completed a Series B Preferred Private Placement, raising $1.7 million from institutional investors [1][2] - The company plans to use the net proceeds of $1.5 million for working capital and general corporate purposes [1][2] - The Series B Convertible Preferred Stock issued has a 10% annual dividend and is convertible into common stock at an initial price of $1.00 per share [2] Financial Position - The CEO stated that the company ended the fiscal year with over $2.2 million in cash, indicating a strengthened balance sheet [2] - The financing is aimed at bolstering shareholder equity and supporting ongoing initiatives for distribution expansion and profitability [2] Company Overview - cbdMD, Inc. is a wellness company offering a range of hemp-derived cannabinoid products, including CBD, CBG, and CBN [4] - The company emphasizes quality, innovation, and transparency, distributing products online and through retail partners across the U.S. [4]